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Abstract
Background: A high proportion of children with persistent diarrhoea in middle and low income
countries die. The best treatment is not clear. We conducted a systematic review to evaluate the
effectiveness of antimicrobial drug treatment for persistent diarrhoea of unknown or non-specific
cause.
Methods: We included randomized comparisons of antimicrobial drugs for the treatment of
persistent diarrhoea of unknown or non-specific cause in children under the age of six years in low
and middle income countries. We searched the electronic databases MEDLINE, EMBASE, LILACS,
WEB OF SCIENCE, and the Cochrane Central Register of Controlled Trials (CENTRAL) to May
2008 for relevant randomized or quasi randomized controlled trials. We summarised the
characteristics of the eligible trials, assessed their quality using standard criteria, and extracted
relevant outcomes data. Where appropriate, we combined the results of different trials.
Results: Three trials from South East Asia and one from Guatemala were included, all were small,
and three had adequate allocation concealment. Two were in patients with diarrhoea of unknown
cause, and two were in patients in whom known bacterial or parasitological causes of diarrhoea
had been excluded. No difference was demonstrated for oral gentamicin compared with placebo
(presence of diarrhoea at 6 or 7 days; 2 trials, n = 151); and for metronidazole compared with
placebo (presence of diarrhoea at 3, 5 and 7 days; 1 trial, n = 99). In one small trial,
sulphamethoxazole-trimethoprim appeared better than placebo in relation to diarrhoea at seven
days and total stool volume (n = 55).
Conclusion: There is little evidence as to whether or not antimicrobials help treat persistent
diarrhoea in young children in low and middle income countries.
Background
In 2002, diarrhoea caused an estimated 13.2% of child
deaths worldwide[1], most of them in children under the
age of five years in low and middle income countries[2].
In this group, around 3% to 19% of acute diarrhoea epi-
sodes become persistent[3] and some experts estimate
that up to 50% of diarrhoea deaths may be due to persist-
ent diarrhoea[1]. As the number of deaths from acute
diarrhoea reduces following widespread use of oral rehy-
dration therapy, the contribution of persistent diarrhoea
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to overall diarrhoea mortality is increasing. Persistent
diarrhoea also adversely affects nutritional status, and is
often associated with malnutrition. In one study, three
months after a persistent diarrhoea episode, children had
significantly lower weight for age and weight for height Z
scores than three months before the episode[4].
Children living in poor areas with poor hygiene and sani-
tation conditions and children with poor nutritional sta-
tus are most at risk of developing persistent diarrhoea[3].
As poor nutrition is both a risk factor and a consequence
of persistent diarrhoea, the two are very commonly asso-
ciated. Children with HIV/AIDS are at particular risk; at
initial presentation to hospital with HIV/AIDS, around
36–50% [5-7] of children have persistent diarrhoea. Dys-
entery and more severe diarrhoeal illness are more likely
to become persistent than milder episodes[3]. Previous
antibiotic use and irrational use of antibiotics for acute
diarrhoea are also considered to be risk factors[3] for per-
sistent diarrhoea.
Definition and causes
The World Health Organization (WHO) defines diar-
rhoea as the passing of three or more loose stools (which
take the shape of a container) within a 24 hour period. A
new episode of diarrhoea can occur after two full days
without diarrhoea. Episodes of diarrhoea lasting for less
than 14 days are defined as acute, episodes lasting for 14
or more days are defined as persistent.
The causes of persistent diarrhoea in populations are com-
plex and poorly understood, and in individuals are often
unknown. Pathogens associated with persistent diarrhoea
are also often found in healthy children without diar-
rhoea[4], a finding highlighted in our related review of
pathogens found in the stool of children with persistent
diarrhoea and without diarrhoea, to be published at a
later date. Some, such as Cryptosporidium, Giardia lamblia
and enteroaggregative Escherichia coli (EAggEC) are
thought to be associated with persistent diarrhoea[3] in
some locations. Children with persistent diarrhoea who
are HIV positive may have different patterns of enteric
pathogens than those who are HIV negative[8]. In addi-
tion, the diarrhoea may be caused by multiple factors:
malnutrition, micronutrient deficiencies, milk or food
intolerance, or diseases of the bowel, as well as prior anti-
microbial therapy[9].
Treatment
The current recommendations of Integrated Management
of Childhood Illness programme[10] for treating diar-
rhoea is that children with bloody diarrhoea are treated
with antimicrobials for Shigella, or for Entamoeba histolyt-
ica where the organism is detected in the stool; it is recom-
mended that children with watery diarrhoea are not
treated with antimicrobials; except where Giardia lamblia
is found.
Even where an enteric pathogen is detected in children
with persistent diarrhoea, it is not always clear that this is
the cause of the illness. In addition, health workers in low
and middle income countries often do not have access to
sufficient high quality diagnostic laboratory facilities to
analyse stool samples for all children with diarrhoea. In
these situations treatment needs to be syndromic, based
on symptoms and the mostly likely cause of the symp-
toms; and may include replacement fluid and electrolytes,
nutritional rehabilitation and sometimes drug treat-
ment[9].
Recent studies have suggested that antimicrobial treat-
ment may be useful in causes of watery diarrhoea other
than Giardia lamblia. For example, there have been prom-
ising trials looking at the use of nitazoxanide for children
with diarrhoea associated with Cryptosporidium  infec-
tion[11], and ciprofloxacin for diarrhoea associated with
enteroaggregative  E.coli  in adults with AIDS[12]. How-
ever, these are yet to be demonstrated in a systematic
review or large scale trial in children with persistent diar-
rhoea. The use of antimicrobials needs to be approached
with caution due to potential problems of drug resistance
and possible reactions of some micro-organisms: entero-
haemorrhagic E coli (EHEC) may release toxins more read-
ily when a person is treated with certain drugs, potentially
causing severe illness[13].
Given the lack of diagnostic facilities, and the consequent
requirement that children presenting to health facilities
with persistent diarrhoea receive only presumptive treat-
ment, we conducted a systematic review. This project was
originally requested by WHO, due to lack of evidence in
this area.
Objective
To assess the effectiveness of antimicrobial drugs for the
treatment of persistent diarrhoea of unknown or non-spe-
cific aetiology in children under the age of six years in low
and middle income countries. Only children under the
age of six were included, because this age group are most
at risk from death or serious morbidity relating to persist-
ent diarrhoea.
Criteria for including studies in this review
Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
Children under the age of six years, with diarrhoea of
unknown or non-specific aetiology longer than 14 days
duration, in a low or middle income country setting (asBMC Infectious Diseases 2009, 9:24 http://www.biomedcentral.com/1471-2334/9/24
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defined by the World Bank). Trials including only partici-
pants with a known cause for their diarrhoea were
excluded. Trials including people of different ages or with
diarrhoea of different durations were included if data
relating only children under the age of six with persistent
diarrhoea could be extracted.
Types of intervention
Intervention: any antimicrobial drug treatment regimen
plus usual care
Control: placebo or usual care
Types of outcome
Primary:
Duration of diarrhoea
Secondary:
Presence of diarrhoea at follow-up
Need for hospitalisation
Stool volume
Death
Adverse events:
Any adverse events
Search strategy for identification of studies
The search strategy was developed in collaboration with
an information retrieval specialist (see below). The strat-
egy listed applies to Medline and was amended where nec-
essary to search the other databases listed. No language
restrictions were applied. The reference lists of included
studies were also scrutinised for additional relevant stud-
ies. The last search was undertaken May 20 2008.
Search Strategy
Databases searched
MEDLINE (1966 to March 2007) via the OVID interface
(table 1 for strategy).
EMBASE (1980 to March 2007) via the OVID interface.
LILACS database – Latin American and Caribbean Health
Sciences Literature (1982 to date) – via Virtual Health
Library interface.
WEB OF SCIENCE (Science Citation Index Expanded –
1945 to present).
Cochrane Central Register of Controlled Trials (CEN-
TRAL), published in The Cochrane Library.
Search strategy in MEDLINE
1. persistent (diarrhea OR diarrhoea) ti, ab.
2. chronic (diarrhea OR diarrhoea) ti, ab.
3. watery (diarrhea OR diarrhoea) ti, ab
4. (diarrheal disease*) OR (diarrhoeal disease*) ti, ab
Table 1: Reasons for excluding reports initially identified as relevant
Reason for exclusion Number of reports
Did not assess the use of antimicrobials 14
Included only patients with a specific cause of diarrhoea 6
Used an alternative definition of persistent diarrhoea 3
Included adults only 3
Included children with acute diarrhoea only 3
Were review articles 3
Had no control group or were case studies 3
Were undertaken in a high income country 1
Relevant controlled trial but no mention of randomization 1BMC Infectious Diseases 2009, 9:24 http://www.biomedcentral.com/1471-2334/9/24
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6. 1 OR 2 OR 3 OR 4) NOT cancer NOT (inflammatory
bowel disease*) NOT (ulcerative colitis)
7. child* OR infant* OR pediatr* ti, ab
8. 6 AND 7
9. Diarrhea, infantile/drug therapy [MeSH] OR Diarrhea,
infantile/prevention and control [MeSH] OR Diarrhea,
infantile/therapy [MeSH]
10. Diarrhea/drug therapy [MeSH] OR Diarrhea/preven-
tion and control [MeSH] OR Diarrhea/therapy [MeSH]
11. therap* OR treatment OR treating ti, ab
12. 9 OR 10 OR 11
13. Anti-Infective Agents/administration and dosage
[MeSH] OR Anti-Infective Agents/adverse effects [MeSH]
OR Anti-Infective Agents/therapeutic use [MeSH])
14. Antiprotozoal Agents/administration and dosage
[MeSH] OR Antiprotozoal Agents/adverse effects [MeSH]
OR Antiprotozoal Agents/therapeutic use [MeSH])
15. Antiparasitic Agents/administration and dosage
[MeSH] OR Antiparasitic Agents/adverse effects [MeSH]
OR Antiparasitic Agents/therapeutic use [MeSH])
16. 12 OR 13 OR 14 OR 15
17. 8 AND 16
18. randomized controlled trial [pt] OR controlled clini-
cal trial [pt] OR randomized controlled trials [MeSH] OR
controlled clinical trials [MeSH] OR random allocation
[MeSH] OR double-blind method [MeSH] OR single-
blind method [MeSH]
OR (placebos [MeSH] OR placebo* ti, ab OR random* ti,
ab OR quasi-random* ti, ab
19. 17 AND 18
Methods
Study selection
Two reviewers independently inspected titles and
abstracts identified in the initial literature search in order
to identify potentially relevant publications. All poten-
tially relevant publications identified by at least one
reviewer were obtained in full text format. One reviewer
then applied the inclusion criteria to select which trials to
include in the review, and scrutinised publications for
duplication of trial results.
Assessment of methodological quality
Two reviewers independently assessed the methodologi-
cal quality of the included trials, using a pro-forma as a
guide. The methodological quality of the included trials
was assessed in terms of generation of the allocation
sequence and allocation concealment and reported as
adequate, inadequate or unclear according to Juni
2001[14]. We recorded who was blinded in each trial. We
classified inclusion of randomized participants in the
analysis as adequate if 80% or more of the participants are
included in the analysis, unclear if not described, and
inadequate if less than 80% were included. Any disagree-
ments were resolved by discussion.
Characteristics of included trials
One reviewer summarised the characteristics of the
included trials. Information was extracted on the trial set-
ting, location, start date, participant characteristics (such
as age, sex and nutritional status), number of participants,
intervention, control and outcomes for each trial. We also
noted any acknowledged sources of financial support for
the trial.
Data extraction
One author extracted outcomes data for the intervention
and control groups. For dichotomous data we extracted
the number of participants with the outcome, the total
number randomized to each group, and the total number
included in the analysis. For continuous data we extracted
the number of participants in each group, the arithmetic
mean and their standard deviations, where available.
Data analysis
The analysis was undertaken using RevMan 4.2 software.
For dichotomous data we calculated relative risks and
where appropriate combined results from different trials.
Where continuous data were summarized by arithmetic
means, we summarized the results using weighted mean
difference (WMD). We stratified the analysis by class of
antimicrobial drug used. We presented data on adverse
events in a narrative summary.
Results
Studies identified
Four trials met our inclusion criteria. The initial search
identified 378 publications, from which we selected 43
that appeared, from their abstracts or titles, to be poten-
tially relevant, for retrieval of the full text. We were unable
to assess three reports due to time constraints, one
because it was not available within the UK, and two, pub-
lished in Polish and Ukrainian respectively, because trans-
lators were not available within the available time period.
Of the 40 papers that we were able to assess, three were
reports of trials eligible for inclusion in the review. The
reasons for the exclusion of the other 37 are summarisedBMC Infectious Diseases 2009, 9:24 http://www.biomedcentral.com/1471-2334/9/24
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in Table 1. We identified one additional eligible trial
through reading the reference lists of retrieved review arti-
cles.
Characteristics of included trials
The characteristics of the four included trials are summa-
rised in Table 2, and also described below.
Location
Three trials were undertaken in the South East Asia region;
two in India[15,16] and one in Bangladesh[17]. Another
was undertaken in Guatemala [18].
Dates of fieldwork
Two trials recruited participants during the period 1988 to
1990[15,18]. Two trial reports did not provide dates for
the fieldwork; these were published in 1995[17] and
1996[16] respectively.
Participants
Each trial included children of a slightly different age
range, the total age range being three months to four
years. Three trials excluded children with diarrhoea lasting
over a certain length of time (18 days[18], 4 weeks[16]
and 6 weeks[17] respectively). Three trials excluded chil-
dren with dysentery or with blood in the stool[15,16,18],
and the other[17] excluded children with Shigella or Enta-
Table 2: Characteristics of Included Trials
Location and date of 
publication
Participants Setting Interventions Outcomes Source of Support
Guatemala
1992 [18]
Number: 102
Girls and boys, 3–35 
mths
Diarrhoea 14–18 
days, weight for length 
not
< -2 Z, no dysentery
Surveillance project: 
rural indigenous 
community
Field nurse visited 
homes three times 
daily to deliver 
intervention
Group 1: 10 mg oral 
gentamicin sulphate 
per kg body weight 
per day: 3× daily for 5 
days.
Group 2: Placebo: 1% 
magnesium sulphate 
3× daily for 5 days.
Diarrhoea stopped at 
7 days, and at least 48 
hrs after end of 
treatment
None stated
India 1992 [15] Number: 68
Boys, 3 mths to 4 yrs
Diarrhoea ≥ 14 days, 
weight for length ≤ 
90% of standard, no 
dysentery
Hospital oral 
rehydration unit in 
New Delhi
Field worker visited 
homes twice daily to 
deliver intervention 
and leave evening 
dose
Group 1: 50 mg oral 
gentamicin per kg 
body weight per day: 
4 times daily for 6 
days
Group 2: Placebo
≤ 2 liquid stools per 
day at 6 days.
Intake of IV fluids, 
ORS, water and 
energy.
Output of diarrhoea, 
vomit and urine.
Weight change at 168 
hrs
Diarrhoeal Diseases 
Control Programme, 
World Health 
Organization
India 1996 [16] Number: 156
Girls and boys, 4 mths 
to 3 yrs
Diarrhoea ≥ 14 days 
<4 weeks, no 
dysentery, Giardia 
lamblia or Entamoeba 
histolytica, no illness 
requiring antibiotics
Surveillance project 
with referrals to clinic 
and direct clinic 
attendances: urban 
slum in Delhi
(outpatients)
Group 1: 30 mg oral 
metronidazole plus 50 
mg oral nalidixic acid 
per kg body weight: 
3× daily for 7 days
Group 2: 30 mg oral 
metronidazole per kg 
body weight: 3× daily 
for 7 days
Group 3: Placebo
First of 3 days with < 
3 liquid stools in a 24 
hrs; days 3, 5 and 7.
No. stools in previous 
24 hrs; days 2, 5 and 
7.
Weight change at days 
7 and 14
CDR, World Health 
Organization
Bangladesh 1995 [17] Number: 55
Girls and boys, 6 to 
15 mths
Diarrhoea ≥ 14 days 
<6 weeks No 
systemic infection, 
antibacterial use 
previous 7 days, 
severe malnutrition, 
Vibrio cholerae, 
Salmonella, Shigella, 
Giardia lamblia or 
Entamoeba histolytica
Clinical research unit 
of specialist diarrhoea 
hospital
(inpatients)
Group 1: 10 mg oral 
trimethoprim plus 50 
mg 
sulphamethoxazole 
per kg body weight; 
2× daily for 7 days
Group 2: Placebo,
Diarrhoea stopped at 
7 days.
Stool output (g/kg) 
days 1,2,3,4,5,6 and 7, 
plus all days 1–7 
combined.
Duration of diarrhoea.
Hospital infection.
Energy intake 
(kcal/kg/day)
United States Agency 
for International 
Development and the 
International Centre 
for Diarrhoeal 
Disease Research, 
BangladeshBMC Infectious Diseases 2009, 9:24 http://www.biomedcentral.com/1471-2334/9/24
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moeba histolytica (the main causes of dysentery). One trial
excluded children described as 'severely malnourished',
another stipulated that weight for length was not less than
-2 Z [17,18], while another included only children who
had weight for length less than or equal to 90% of the
standard [15]. Two trials excluded children with systemic
infection[16,17], and one excluded children who had
taken antibiotics in the previous seven days[17]. Two
excluded children with specific enteric pathogens (Giardia
lamblia and Entamoeba histolytica in one[16], Giardia lam-
blia, Entamoeba histolytica, Vibrio cholerae, Salmonella and
Shigella another[17]). None included specifically children
with HIV/AIDS.
Settings
Participants were recruited from a range of sources includ-
ing a diarrhoea surveillance project within a rural indige-
nous community[18], referrals to a hospital rehydration
unit[15], and attendance at a clinic provided as part of a
surveillance project in an urban slum[16]. In one trial it
was not clear how the participants were recruited[17]
Comparisons
Two trials compared gentamicin with placebo[15,18], one
three-arm trial compared metronidazole, metronidazole
combined with nalidixic acid, and placebo[16], and one
trial compared sulphamethoxazole-trimethoprim with
placebo[17]. All antimicrobials were given orally for
between five and seven days.
Outcomes
Only one trial reported on our primary outcome of dura-
tion of diarrhoea[17]. All four trials reported on recovery
from diarrhoea by the end of treatment; one trial also
assessed diarrhoea at three and five days[16]. Three trials
reported on stool output at various time points; two meas-
ured stool weight[15,17], and one measured number of
stools[16]. In addition, two trials reported on weight gain
at different time intervals[15,16], one reported on various
fluid intakes and outputs[15], two reported on energy
intake[15,17], and one reported on hospital-acquired
infections[17]. Two trials recorded and reported on
adverse events[15,18].
Sources of support
Two trials were supported by the World Health Organiza-
tion[15,16], one by the United States Agency for Interna-
tional Development and International Centre for
Diarrhoeal Disease Research[17], and one did not men-
tion a source of support[18]. None acknowledged support
from pharmaceutical companies.
Quality assessment
A summary of the methodological quality assessment for
each study is presented in Table 3. All four studies
described blinding the participants to which group they
were in, and including over 80% of the randomized par-
ticipants in the main analyses. Three studies also reported
adequate generation of allocation sequence, allocation
concealment and blinding of service providers and out-
comes assessors. The remaining study[16] was unclear on
these methodological issues, but stated that it used rand-
omization, and that it used coded antimicrobial and pla-
cebo preparations, which were identical in appearance.
Outcomes
Oral gentamicin versus placebo
Two trials[15,18] compared oral gentamicin (10 mg/kg
body weight in one trial and 50 mg/kg body weight in the
other) versus placebo. Both trials assessed and reported
on presence of diarrhoea at end of treatment (6 or 7 days).
Combining the results of the two trials, there was no dif-
ference between the gentamicin and placebo groups in the
number of children with diarrhoea at the end of treatment
(relative risk 1.04, 95% CI 0.78 to 1.38, 151 participants);
around half the children in both groups recovered within
six or seven days. There was no difference in point esti-
mates between the two trials, one of which excluded chil-
dren with weight for length less than -2 Z and used a
standard dose of gentamicin [18], (RR = 0.01), and one of
which included only children with weight for length equal
to or less than 90% of the standard and used a massive
Table 3: Methodological quality assessment of included trials
Location and reference Generation of allocation 
sequence
Concealment of allocation Blinding Percentage of participants 
included in the analysis
Participants Providers Outcomes assessors
Guatemala [17] Adequate Adequate Yes Yes Yes Adequate
India [14] Adequate Adequate Yes Yes Yes Adequate
India [15] Unclear Unclear Yes Unclear Unclear Adequate
Bangladesh [16] Adequate Adequate Yes Yes Yes AdequateBMC Infectious Diseases 2009, 9:24 http://www.biomedcentral.com/1471-2334/9/24
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dose of gentamicin with the aim of eradicating aerobic
bacterial overgrowth of the small intestine [15] (RR =
0.10). There were also no significant differences between
groups in any reported measure of weight gain, fluid
intake, energy intake, or fluid output.
One trial reported no drug-related untoward effects[18].
The other reported no clinical toxicity, and blood urea
concentrations similar in the treatment and placebo
groups[15].
Metronidazole combined with nalidixic acid versus metronidazole 
alone versus placebo alone
One trial[16] compared three treatment groups: metroni-
dazole combined with nalidixic acid, metronidazole
alone and placebo. There was no significant difference
between the groups in the primary outcome of time to
recovery, or in the number of children with diarrhoea at
three, five or seven days, although point estimates tended
to favour the group receiving metronidazole combined
with nalidixic acid.
There were no significant differences between groups in
the mean number of stools in the previous 24 hours at
three days or five days; at seven days the group receiving
metronidazole combined with nalidixic acid had fewer
stools than the group receiving metronidazole alone but
the difference was small (mean difference -1.10, 95% con-
fidence interval -2.07 to -0.13, 99 participants), and not
significantly different when compared with the placebo
group. There were no differences between the groups in
percentage weight gain at seven and 14 days.
Adverse events were not mentioned in the report of this
trial.
Sulphamethoxazole-trimethoprim versus placebo
One trial compared sulphamethoxazole-trimethoprim
with placebo[17]. Significantly fewer children in the treat-
ment group had diarrhoea at the end of treatment (7 days)
(relative risk 0.4, 95% confidence interval 0.16 to 0.99, 55
participants). This related to an 82% cure rate in the anti-
microbials group and 55% cure rate in the placebo group.
Duration of diarrhoea also appeared to favour treatment,
but the difference was not significant. Total stool output
in the seven days following start of treatment was signifi-
cantly lower in the treatment group (mean difference -
179.4 g, 95% confidence interval -340.20 to -18.60).
Participants in the treatment group had a significantly
lower risk of acquiring infections while in hospital com-
pared with placebo (relative risk 0.06, 95% confidence
interval 0.01 to 0.54); while energy intake from the hospi-
tal diet was similar in both groups.
Adverse events were not mentioned in the report of this
trial.
Discussion
Despite the comprehensive search strategy used, we iden-
tified only four trials assessing the use of antimicrobials
for children with persistent diarrhoea in low and middle
income countries; all of which were conducted in the late
1980s and early 1990s. All four trials used good quality
methods to minimise the risk of bias. However, they are
also all quite small, involving between 55 and 156 partic-
ipants; and so the effect estimates are consequently impre-
cise. Two trials excluded children with certain laboratory-
confirmed pathogens known to cause diarrhoea found in
the stool, while the other two trials did not test the partic-
ipants for specific pathogens. Two trials included only
children with associated malnutrition or low weight for
height. None of the studies included children with known
HIV/AIDS.
In a related review that has been submitted for publica-
tion, we examined the frequency of different pathogens
found in children with persistent diarrhoea and no diar-
rhoea. We found that, while children with persistent diar-
rhoea are more likely to have at least one detectable
enteric pathogen than children without diarrhoea, for spe-
cific pathogens there were no significant differences
between the two groups; both exhibit a wide range of dif-
ferent pathogens in the stool, including bacteria, parasites
and viruses. These findings suggest that antimicrobial
therapy may be of limited effectiveness in the majority of
children with persistent diarrhoea. Trials of oral gen-
tamicin, a non-absorbable drug effective against a wide
range of bacteria, have tended to confirm this. Small trials
of sulphamethoxazole-trimethoprim, and metronidazole
combined with nalidixic acid have suggested some poten-
tially worthwhile effects, which have not been tested in
larger trials. Both these combinations are absorbable and
effective against a wide range of bacteria; possible modes
of action therefore include direct action on the enteric
pathogens, and also on any systemic infections which
may be delaying the child's recovery from diarrhoea.
Conclusion
There is limited evidence as to whether or not antimicro-
bials help to reduce the duration of persistent diarrhoea or
reduce its health impact in young children in developing
countries, either in children with a symptomatic diagnosis
of persistent diarrhoea where no laboratory exists, or in
children with persistent diarrhoea in whom known bacte-
rial and parasitic causes have been excluded. There is cur-
rently insufficient data to recommend the use of any kind
of antibiotic in persistent diarrhoea of unknown cause or
non-specific cause, and hence no implications for current
guidelines on the treatment of persistent diarrhoea.BMC Infectious Diseases 2009, 9:24 http://www.biomedcentral.com/1471-2334/9/24
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Further good quality trials, of sufficient sample size to
detect clinically important effect sizes, are needed to eval-
uate the use of antimicrobials in the presumptive treat-
ment of persistent diarrhoea. These trials should be
conducted in areas where persistent diarrhoea is common
in young children, and where testing for enteric pathogens
is not routinely available. Children with HIV/AIDS should
be included. Trials should first assess the treatment com-
binations that have already given encouraging results in
previous, smaller trials, and then perhaps other wide-
spectrum antimicrobial drug combinations. Outcomes
should include nutritional recovery, which will require a
longer period of follow-up than that of the trials included
in this review. Monitoring of emerging pathogen resist-
ance should be undertaken within these trials.
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